Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1918-1924

  Carvajal, Daisy ^a   Tovar, Christian ^a   Yang, Hong ^a   Vu, Binh T ^a   Heimbrook, David C ^a   Vassilev, Lyubomir T ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUTLIN; PACLITAXEL; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROTECTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENCY; DRUG SELECTIVITY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; INCUBATION TIME; MITOSIS INDEX; MITOSIS INHIBITION; PRIORITY JOURNAL; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; G1 PHASE; G2 PHASE; HUMANS; IMIDAZOLES; MITOSIS; MUTATION; NUCLEAR PROTEINS; PACLITAXEL; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16444380911     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3576     Document Type: Article

References (28)

1. Pardee AB, Dubrow R, Hamlin JL, Kletzien RF. Animal cell cycle. Annu Rev Biochem 1978;47:715-50.
2. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4.
3. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair 2004;3:997-1007.
4. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001;61:4301-5.
5. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 2002;1:375-82.
6. Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog Cell Cycle Res 2003;5:527-32.
7. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000;105:533-9.
8. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
9. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
10. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
11. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-60.
12. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
13. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
14. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 1998;13:49-58.
15. Picksley SM, Lane, DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 1993;15:689-90.
16. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
17. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
18. Vassilev LT, Kazmer S, Marks IM, et al. Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors. Anticancer Drug Des 2001;16:7-17.
19. Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2001;5:309-25.
20. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
21. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004;3:419-21.
22. 1 arrest. Cancer Res 1998;58:396-401.
23. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 2004;92:8493-7.
24. 2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002;21:6249-54.
25. Perego P, Corna E, De Cesare M, et al. Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 2004;8:31-7.
26. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80.
27. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
28. 1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res 2004;59:3831-7.